BioStem Technologies announced participation in the Symposium on Advanced Wound Care Spring meeting in Charlotte, NC, from April 8-12, 2026, where the company will highlight its recently introduced Neox Product line. According to Chairman and CEO Jason Matuszewski, this addition reinforces the company's focus on advancing science and equipping clinicians with data and tools to improve patient outcomes. The expanded portfolio offers what BioStem describes as the most comprehensive suite of placental and umbilical cord tissue solutions, backed extensively by both randomized clinical trials and real-world evidence.
The company will host a lunch symposium titled "A New Season in Wound Care: An Expanded Portfolio Grounded in Evidence" on Thursday, April 9th, featuring presentations by Dr. Wendy Weston, William Marston, MD, and Herbert Slade, MD. The session will include discussion of the newly expanded product portfolio, the science behind its birth tissue products, recently published results of a randomized controlled trial on diabetic foot ulcers, and practical guidance on incorporating these therapies into clinical practice. BioStem will also present a new scientific poster presentation available for viewing in Exhibit Hall 1C, demonstrating its continued investment in clinical research and medical education.
BioStem's participation in SAWC, one of the premier gatherings for wound care professionals, clinicians, and researchers, represents an opportunity to share clinical evidence supporting its technologies. The company's quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks and are established in compliance with current Good Tissue Practices and current Good Manufacturing Processes. BioStem's portfolio of quality brands includes its Neox, Clarix, VENDAJE and American Amnion product lines, developed using proprietary BioRetain, CryoTek and SteriTek processing technologies designed to optimize preservation of natural tissue properties.
The Neox Product line expands BioStem's capabilities across multiple tissue formats and provides physicians with differentiated options depending on clinical needs. This matters because it represents a significant advancement in wound care treatment options, particularly for challenging conditions like diabetic foot ulcers where evidence-based solutions are critical. The company's emphasis on both randomized clinical trials and real-world evidence provides clinicians with confidence in treatment efficacy and safety profiles. Additional information about the company is available at https://www.biostemtechnologies.com while the latest news and updates relating to the company are available at https://tinyurl.com/bsemnewsroom.
